You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
CRBN PROTAC® 14a
生物活性 for CRBN PROTAC® 14a
CRBN PROTAC® 14a is a cereblon Degrader (PROTAC®). Comprises a ligand for Von Hippel Lindau (VHL) protein joined by a linker to a cereblon targeting ligand. Preferentially degrades cereblon (DC50 = 200 nM in HEK293 cells). Induces rapid and profound cereblon degradation (98% decrease after 8 h at 1 μM in HEK293 cells).
PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
Sold under licence from the University of Dundee
技术数据 for CRBN PROTAC® 14a
|储存||Store at -20°C|
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶解性数据 for CRBN PROTAC® 14a
|溶剂||最高浓度 mg/mL||最高浓度 mM|
制备储备液 for CRBN PROTAC® 14a
以下数据基于产品分子量 1061.26。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|浓度/溶剂体积/质量||1 mg||5 mg||10 mg|
|1 mM||0.94 mL||4.71 mL||9.42 mL|
|5 mM||0.19 mL||0.94 mL||1.88 mL|
|10 mM||0.09 mL||0.47 mL||0.94 mL|
|50 mM||0.02 mL||0.09 mL||0.19 mL|
参考文献 for CRBN PROTAC® 14a
Girardini et al (2019) Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs. Bioorg.Med.Chem. 27 2466 PMID: 30826187
If you know of a relevant reference for CRBN PROTAC® 14a, please let us know.
关键词: CRBN PROTAC® 14a, CRBN PROTAC® 14a supplier, PROTACs, PROTAC, proteolysis, targeting, chimera, active, Degrader, Degraders, degrading, VHL, von, Hippel, Lindau, Cereblon, CRBN, targeted, protein, degradation, TPD, Active, Ubiquitin, E3, Ligases, 7219, Tocris Bioscience
篇 CRBN PROTAC® 14a 的引用文献
引用文献是使用了 Tocris 产品的出版物。
目前没有 CRBN PROTAC® 14a 的引用文献。 您是否知道使用了 Tocris CRBN PROTAC® 14a 的优秀论文？ 请告知我们.
CRBN PROTAC® 14a 的评论
目前没有该产品的评论。 Be the first to review CRBN PROTAC® 14a and earn rewards!
Have you used CRBN PROTAC® 14a?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
Targeted Protein Degradation Research Product Guide
This brochure highlights the tools and services available from Bio-Techne to support Targeted Protein Degradation research, including:
- Active Degraders
- TAG Degradation Platform
- Degrader Building Blocks
- Custom Degrader Services
- Ubiquitin-Proteasome System Proteins and Assays
- Assays for Protein Degradation
Epigenetics Scientific Review
Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.
Epigenetics in Cancer Poster
Adapted from the 2015 Cancer Product Guide Edition 3, this poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.
Targeted Protein Degradation Poster
Degraders (e.g. PROTACs) are bifunctional small molecules, that harness the Ubiquitin Proteasome System (UPS) to selectively degrade target proteins within cells. They consist of three covalently linked components: an E3 ubiquitin ligase ligand, a linker and a ligand for the target protein of interest. Authored in-house, this poster outlines the generation of a toolbox of building blocks for the development of Degraders. The characteristics and selection of each of these components are discussed. Presented at EFMC 2018, Ljubljana, Slovenia